Hanna L Kleiboeker

11PUBLICATIONS
6CO-AUTHORS
Nanotoxicology, health and safetyGene and molecular therapyCancer therapy (excl. chemotherapy and radiation therapy)Predictive and prognostic markersMedical virology
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (11)

|Mar 16, 2026
Beyond Thresholds: CMV Replication Kinetics as Early Predictors of Clinical Risk in Transplant Recipients.

Hanna L Kleiboeker, Jillian L Descourouez, Chris Saddler

|Dec 18, 2025
De Novo Letermovir After Cytomegalovirus Seropositive Kidney Transplant Improves Toxicity and Mycophenolate Tolerance Over the Current Standard of Care.

Hanna L Kleiboeker, Margaret R Jorgenson, Michael J Scolarici

|Nov 27, 2024
Impact of Letermovir for Cytomegalovirus Primary Prophylaxis on Myelosuppression and Immunosuppression in Lung Transplant Recipients.

Hanna L Kleiboeker, Alyson Prom, Krista Paplaczyk

|Aug 13, 2024
Efficacy of dose-reduced glecaprevir-pibrentasvir in lung transplant recipients on maintenance cyclosporine from donors with hepatitis C viremia.

Hanna L Kleiboeker, Alyson Prom, Sonalie Patel

|Jul 09, 2024
Use of letermovir for cytomegalovirus primary prophylaxis in lung transplant recipients.

Hanna L Kleiboeker, Jacob Wang, Nicole Borkowski

|Mar 02, 2024
Development of cytomegalovirus resistant to maribavir: real world, real problem?

Hanna L Kleiboeker, Alyson Prom, Krista Paplaczyk

Pageof 2

Frequent Collaborators

5 joint publications

Margaret R Jorgenson

2 joint publications

Jeannina A Smith

2 joint publications

Didier Mandlebrot

2 joint publications

Krista Paplaczyk